ABEONA THERAPEUTICS INC. Impairment of Long-Lived Assets to be Disposed of
ABEONA THERAPEUTICS INC. (ABEO) reported Impairment of Long-Lived Assets to be Disposed of of $1.40 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2023-03-29
- ABEONA THERAPEUTICS INC. impairment of long-lived assets to be disposed of for fiscal 2022 was $1.40M.
| Period end | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|
| 2022-12-31 | $1.40M 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |